MRI 유도하 집속초음파((MRgFUS) 시장 : 메커니즘, 제공 내용, 최종사용자, 적응증별 - 예측(2026-2032년)

The Magnetic Resonance Guided Focused Ultrasound Therapy System Market was valued at USD 597.28 million in 2025 and is projected to grow to USD 684.24 million in 2026, with a CAGR of 13.88%, reaching USD 1,483.72 million by 2032.

A concise orientation to MR-guided focused ultrasound as a convergent therapeutic platform shaping clinical pathways, institutional readiness, and translational research

Magnetic resonance guided focused ultrasound (MRgFUS) is transitioning from a niche investigational modality to a cornerstone of minimally invasive therapeutic strategies across multiple clinical specialties. This introduction frames the technology as a convergence of high-resolution imaging, precise energy delivery, and evolving clinical protocols that together enable targeted tissue ablation, neuromodulation, and facilitation of novel drug delivery techniques. The narrative that follows positions MRgFUS not just as a device category but as an integrative platform that interfaces with imaging, surgical workflows, and translational research.

Over recent years, momentum has been driven by iterative improvements in MR imaging sequences, enhanced patient workflow integration, and growing clinical evidence across indications ranging from benign gynecologic disease to neurologic conditions. Stakeholders across institutional, research, and commercial settings are assessing how MRgFUS can reduce procedural morbidity, shorten recovery times, and enable previously infeasible therapeutic pathways. As adoption accelerates, strategic questions about site of care readiness, training requirements, reimbursement pathways, and supply chain resilience become central to implementation planning.

This introduction sets the context for deeper analysis of market dynamics, technology differentiation, regulatory headwinds, and competitive positioning. It underscores the need for cross-functional alignment among clinicians, imaging teams, hospital administrators, and commercial partners to convert clinical promise into sustainable clinical programs and reproducible patient outcomes.

How clinical validation, modular architectures, and cross-disciplinary partnerships are reshaping adoption pathways and commercial competition in MR-guided focused ultrasound

The MRgFUS landscape is experiencing transformative shifts driven by clinical validation, modular technology architectures, and expanding therapeutic ambitions. Clinical evidence is broadening from isolated case series to multicenter experiences that validate efficacy and safety across neuro-oncology, movement disorders, and oncologic indications. As a result, institutional adoption is being reimagined: centers are evaluating MRgFUS not only for discrete procedures but as a capability that can be integrated into surgical suites, interventional radiology workflows, and research cores.

Technological evolution is also reshaping the competitive environment. Systems are migrating toward more modular offerings that enable retrofit integration and hybrid imaging guidance, while software advances in treatment planning and real-time monitoring increase procedural confidence. Concurrently, translational initiatives such as blood-brain barrier modulation and microbubble-mediated delivery are expanding the potential therapeutic payloads that MRgFUS can support, creating new intersections with pharmaceutical development and oncology research programs.

Operationally, there is a pronounced shift toward decentralized care models and ambulatory procedural settings for appropriate indications. This transition is tempered by the need for robust training programs, service-level agreements, and cross-disciplinary governance to ensure patient safety and reproducible outcomes. Taken together, these shifts indicate a maturing ecosystem where clinical utility, interoperability, and strategic partnerships determine long-term value rather than simple technology possession.

Assessing the supply chain, procurement, and commercial model adjustments prompted by cumulative United States tariff measures affecting MR-guided focused ultrasound in 2025

The cumulative impact of tariff actions in 2025 presents a complex set of operational and strategic considerations for stakeholders in the MRgFUS value chain. Tariffs on imported components, imaging subsystems, and precision manufacturing inputs increase the cost basis for systems manufacturers and can reverberate through distribution channels. These cost pressures frequently prompt manufacturers to reassess supplier footprints, accelerate localization of critical components, and renegotiate supply agreements to preserve gross margins and avoid abrupt price shifts for institutional buyers.

Beyond direct cost implications, tariffs create timing and logistics challenges. Procurement cycles for capital equipment tend to be long, and uncertainty around duties can delay purchases or prompt institutions to favor already-localized vendors. For manufacturers that rely on specialized overseas expertise for assembly or calibration, tariffs can incentivize nearshoring or the establishment of regional service hubs to maintain competitiveness. These adaptive strategies require upfront investment but can yield more resilient supply chains over time.

Regulatory and contracting processes are also affected. Hospitals and ambulatory centers operating under fixed capital budgets may defer acquisitions during periods of tariff volatility, impacting revenue cycles for providers that offer MRgFUS as a service. In response, vendors are increasingly offering flexible commercial models, including consumable revenue streams, managed service agreements, and phased financing structures to mitigate buyer uncertainty. Ultimately, the tariff environment in 2025 acts as an accelerant for supply chain redesign, regional manufacturing strategies, and commercial model innovation, compelling stakeholders to prioritize agility and diversified sourcing.

Deep segmentation insights revealing how end-user specialties, therapeutic mechanisms, product offerings, and clinical indications shape adoption, evidence needs, and commercialization tactics

A robust segmentation framework reveals nuanced implications for clinical adoption, product development, and commercialization across end users, mechanisms, offerings, and indications. When viewing the market through end-user lenses, ambulatory surgical centers emerge with sub-specializations such as cancer centers and imaging centers that prioritize throughput, patient experience, and predictable procedure times, while hospitals, both private and public, focus on integration with complex care pathways and institutional credentialing. Research institutes split between academic research institutions and pharmaceutical R&D labs, emphasizing translational studies and partnerships for drug delivery, and specialty clinics like neurosurgery and oncology centers concentrate on high-acuity cases and multidisciplinary coordination.

Mechanism-based segmentation clarifies development trajectories and clinical partnerships. Platforms enabling blood-brain barrier opening with reversible disruption attract collaborations with neurologists and pharmaceutical developers pursuing targeted CNS delivery. Drug delivery mechanisms, including encapsulated carriers, microbubble-mediated techniques, and targeted delivery platforms, link closely with translational research and clinical trial design. Histotripsy, characterized by cavitation-induced tissue fractionation, and neuromodulation approaches spanning deep brain stimulation analogs and noninvasive techniques, each require distinct regulatory strategies and clinician training. Thermal ablation, delivered through focused ultrasound ablation methods, aligns with surgical and oncologic workflows and tends to be the most familiar entry point for surgical teams.

Offering segmentation differentiates commercial models and lifecycle support requirements. Accessories and parts, encompassing accessories, consumables, and replacement parts, create recurring revenue opportunities and necessitate robust logistics. Services such as consulting and training as well as installation and maintenance are critical to adoption, particularly for institutions implementing complex imaging-guided procedures. Systems themselves bifurcate between MR-guided systems and ultrasound-guided systems; MR-guided platforms further diverge into fully integrated and retrofit systems, while ultrasound-guided offerings distinguish between integrated coils and standalone systems. Each subcategory carries implications for capital planning, staff competencies, and service ecosystems.

Indication-driven segmentation highlights clinical prioritization and evidence generation pathways. Applications range from bone metastases, breast cancer, essential tremor, liver tumors, pancreatic tumors, prostate cancer, and uterine fibroids to a spectrum of neurological disorders. Within neurological disorders, subcategories such as brain tumors, movement disorders, neuropathic pain, and Parkinson's disease require bespoke trial designs, multidisciplinary care pathways, and long-term outcome tracking. Mapping these segments against payer landscapes and institutional capabilities enables targeted commercialization and clinical research strategies that align with patient need and reimbursement viability.

How regional regulatory diversity, infrastructure priorities, and clinical collaboration models across the Americas, EMEA, and Asia-Pacific influence adoption and commercialization strategies

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategy, and commercial execution. In the Americas, institutional investment appetite is tempered by reimbursement frameworks, clinical guideline evolution, and the maturity of interventional radiology and neurosurgical centers. Patient demand in tertiary referral centers and integrated cancer programs is converging with interest from ambulatory surgical models that can offer lower-cost, high-throughput care for select indications. These forces shape vendor go-to-market priorities and the structuring of service agreements to align with hospital procurement cycles.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory alignment across distinct national health systems and centralized procurement in some countries coexist with highly specialized private providers in others. Clinical adoption is often influenced by national guideline endorsements and demonstration projects within academic centers that then catalyze broader uptake. Service and training partnerships are particularly important in this region, as centers seek capacity-building support to translate clinical evidence into routine practice.

Asia-Pacific is characterized by rapid infrastructure investment, an expanding base of advanced imaging centers, and strong government-led initiatives to bolster domestic manufacturing capabilities. Several markets within the region are prioritizing localized production and skills development, which creates potential opportunities for manufacturers prepared to invest in localized support. Across all regions, cross-border collaborations in clinical research and shared registries are emerging as critical mechanisms for accelerating evidence generation and harmonizing best practices.

Competitive ecosystem analysis emphasizing how manufacturers, innovative entrants, and strategic partnerships drive technology differentiation, service models, and clinical collaboration

Key company dynamics are defined less by singular market leaders and more by an ecosystem of device manufacturers, imaging partners, clinical research organizations, and specialized service providers. Established medical device manufacturers bring strengths in regulatory experience, global service networks, and capital access, which enable them to scale complex installations and offer integrated maintenance contracts. At the same time, innovative startups are driving differentiation through focused clinical programs, algorithmic treatment planning, and novel mechanisms such as enhanced blood-brain barrier modulation and microbubble-assisted delivery.

Strategic partnerships are increasingly central to competitive positioning. Collaborations between device vendors and pharmaceutical developers create co-development pathways for indications that marry focused ultrasound delivery with targeted therapeutics. Similarly, alliances with imaging vendors and systems integrators facilitate smoother workflow integration and reduce adoption friction at hospital sites. Service providers that specialize in training and clinical workflow optimization add value by shortening the learning curve for new adopters and improving first-case success rates.

Given the capital intensity of system deployment, companies that offer flexible commercial arrangements-leasing, managed services, or outcome-linked models-can accelerate adoption among budget-constrained institutions. The competitive landscape also rewards firms that invest in robust real-world evidence programs and registries, as longitudinal clinical outcomes will increasingly inform payer decisions and guideline formulation.

Actionable strategic playbook for industry leaders to accelerate adoption, anchor clinical partnerships, and de-risk commercial and supply chain execution in MRgFUS

Industry leaders should adopt a multi-pronged strategy that aligns technology development, clinical evidence generation, and commercial flexibility to accelerate adoption and de-risk investment. First, prioritize modular product architectures and retrofit options that reduce upfront capital barriers for health systems, enabling faster proof-of-concept deployments in academic and high-volume community centers. This approach should be complemented by targeted training and certification programs that reduce variability in clinical outcomes and build institutional champions.

Second, invest in strategic alliances with pharmaceutical developers and translational research centers to co-design trials that demonstrate the unique value proposition of combining focused ultrasound with targeted therapeutic agents. These collaborations can open new reimbursement pathways and create differentiated clinical indications that are difficult for competitors to replicate. Simultaneously, vendors should develop comprehensive service models that include installation, ongoing maintenance, and clinical workflow consultancy to minimize operational friction and maximize uptime.

Third, diversify supply chains and consider regional manufacturing or assembly hubs to mitigate tariff exposure and logistics risk. Building local service capabilities reduces time-to-repair and strengthens relationships with institutional purchasers. Finally, adopt data-driven commercialization strategies: deploy registries, real-world evidence collection, and outcome analytics to demonstrate long-term value and support payer negotiations. By executing these recommendations, industry leaders can create a defensible market position that balances innovation with scalability.

Transparent description of a mixed-methods research approach combining primary clinical interviews, secondary evidence synthesis, and expert validation to ensure robust actionable insights

The research methodology underpinning this executive summary integrates primary qualitative engagement, rigorous secondary analysis, and iterative expert validation to ensure credibility and practical relevance. Primary inputs were gathered through structured interviews with clinical leaders across neurosurgery, interventional radiology, and oncology, as well as procurement and technical operations stakeholders who manage imaging suites and capital planning processes. These conversations provided firsthand insights into clinical workflows, training needs, and procurement decision criteria.

Secondary research reviewed peer-reviewed clinical literature, regulatory filings, device technical specifications, and publicly available clinical guidelines to triangulate clinical efficacy, safety considerations, and regulatory pathways. Market intelligence was synthesized by mapping technology roadmaps, patent activity, and partnerships to identify strategic trends and innovation vectors. Data triangulation and cross-validation steps reconciled divergent perspectives and ensured that conclusions reflected both clinical realities and commercial imperatives.

Finally, findings were subjected to expert panel review, where thought leaders from clinical, regulatory, and commercial domains critiqued assumptions, validated segmentation frameworks, and recommended interpretative adjustments. Quality controls included source provenance tracking, conflict-of-interest assessments for interviewees, and iterative revisions to ensure clarity and actionable relevance for decision-makers seeking to deploy or invest in MRgFUS capabilities.

Synthesis and forward-looking assessment highlighting the coordinated actions required from manufacturers, clinicians, and payers to realize sustained MRgFUS adoption

In conclusion, MR-guided focused ultrasound stands at an inflection point where clinical innovation, commercialization strategy, and operational execution intersect to determine the pace and scale of adoption. Clinical evidence expansion, modular technology trends, and strategic collaborations with pharmaceutical and imaging partners are collectively redefining what is possible for noninvasive therapies and targeted drug delivery. Institutional adoption will hinge on the ability of stakeholders to integrate technology into clinical pathways while ensuring consistent training, service reliability, and outcome measurement.

External forces such as tariff environments, regional regulatory diversity, and capital procurement practices will shape vendor strategies around localization, flexible commercial terms, and service offerings. Companies that proactively address supply chain resilience, invest in real-world evidence, and design scalable training programs will be best positioned to convert clinical promise into routine care. For health systems and research institutions, the imperative is to align clinical priorities with measurable outcome goals and to leverage strategic partnerships that accelerate translational research and patient access.

Overall, the pathway to broad adoption depends on coordinated efforts across manufacturers, clinical champions, service providers, and payers to demonstrate sustained clinical benefit, operational viability, and economic value. Stakeholders who act decisively to address these dimensions will shape the next generation of therapeutic care enabled by MRgFUS.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Mechanism

• 8.1. Blood Brain Barrier Opening
• 8.2. Drug Delivery
  • 8.2.1. Encapsulated Drug Carriers
  • 8.2.2. Microbubble Mediated Delivery
  • 8.2.3. Targeted Delivery
• 8.3. Histotripsy
• 8.4. Neuromodulation
  • 8.4.1. Deep Brain Stimulation
  • 8.4.2. Non Invasive Neuromodulation
• 8.5. Thermal Ablation

9. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Offering

• 9.1. Accessories And Parts
  • 9.1.1. Accessories
  • 9.1.2. Consumables
  • 9.1.3. Replacement Parts
• 9.2. Services
  • 9.2.1. Consulting And Training
  • 9.2.2. Installation And Maintenance
• 9.3. Systems
  • 9.3.1. MR Guided Systems
  • 9.3.2. Ultrasound Guided Systems

10. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by End User

• 10.1. Ambulatory Surgical Centers
  • 10.1.1. Cancer Centers
  • 10.1.2. Imaging Centers
• 10.2. Hospitals
  • 10.2.1. Private Hospitals
  • 10.2.2. Public Hospitals
• 10.3. Research Institutes
  • 10.3.1. Academic Research Institutes
  • 10.3.2. Pharmaceutical R&D Labs
• 10.4. Specialty Clinics
  • 10.4.1. Neurosurgery Centers
  • 10.4.2. Oncology Centers

11. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Indication

• 11.1. Bone Metastases
• 11.2. Breast Cancer
• 11.3. Essential Tremor
• 11.4. Liver Tumors
• 11.5. Neurological Disorders
  • 11.5.1. Brain Tumors
  • 11.5.2. Movement Disorders
  • 11.5.3. Neuropathic Pain
  • 11.5.4. Parkinsons Disease
• 11.6. Pancreatic Tumors
• 11.7. Prostate Cancer
• 11.8. Uterine Fibroids

12. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Magnetic Resonance Guided Focused Ultrasound Therapy System Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Magnetic Resonance Guided Focused Ultrasound Therapy System Market

16. China Magnetic Resonance Guided Focused Ultrasound Therapy System Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Alpinion Medical Systems Co., Ltd.
• 17.6. Canon Medical Systems Corporation
• 17.7. Chongqing Haifu Technology Co., Ltd.
• 17.8. EDAP TMS SA
• 17.9. EDAP-affiliated product lines
• 17.10. EpiSonica
• 17.11. EyeTechCare
• 17.12. FUJIFILM Holdings
• 17.13. FUS Instruments
• 17.14. General Electric Company
• 17.15. Hitachi, Ltd.
• 17.16. Insightec Ltd.
• 17.17. Koninklijke Philips N.V.
• 17.18. Medtronic plc
• 17.19. Mianyang Sonic Electronic
• 17.20. Mirabilis Medical
• 17.21. Profound Medical
• 17.22. Shanghai A&S Science & Technology
• 17.23. Shenzhen Wikkon Medical Technology
• 17.24. Siemens Healthineers AG
• 17.25. SonaCare Medical
• 17.26. SuperSonic Imagine
• 17.27. Theraclion SA